Skip to main content
NCBI home page
British Journal of Cancer logoLink to British Journal of Cancer
. 1975 Apr;31(4):387–404. doi: 10.1038/bjc.1975.78

Immunity to murine sarcoma virus induced tumours. IV. Direct cellular cytolysis of 51Cr labelled target cells in vitro and analysis of blocking factors which modulate cytotoxicity.

R M Gorczynski, R A Knight
PMCID: PMC2009458  PMID: 50851

Abstract

The antigen specific cell mediated cytotoxicity of MSV immune spleen lymphocytes to 51Cr labelled murine lymphoma cells was wholly abolished by pretreatment of the spleen cells with anti-theta antibody and complement. Early during the immune response to MSV the cytotoxic acitivity was inhibited by incubation of immune lymphocytes with "late progressor" or "early regressor" serum. Immune lymphocytes at later times were more refractory to such inhibition by serum blocking factors. Although unfractionated cytotoxic lymphocytes, irrespective of the time after MSV infection at which they were tested, were inhibited by soluble tumour associated antigen (TAA), a subpopulation of cytotoxic T cells was identified which was inhibited neither by antigen nor serum.

Full text

PDF
387

Selected References

These references are in PubMed. This may not be the complete list of references from this article.

  1. Aoki T., Herberman R. B., Johnson P. A., Liu M., Sturm M. M. Wild-type gross leukemia virus: classification of soluble antigens (GSA). J Virol. 1972 Dec;10(6):1208–1219. doi: 10.1128/jvi.10.6.1208-1219.1972. [DOI] [PMC free article] [PubMed] [Google Scholar]
  2. Boyle W. An extension of the 51Cr-release assay for the estimation of mouse cytotoxins. Transplantation. 1968 Sep;6(6):761–764. doi: 10.1097/00007890-196809000-00002. [DOI] [PubMed] [Google Scholar]
  3. Cerottini J. C., Nordin A. A., Brunner K. T. Specific in vitro cytotoxicity of thymus-derived lymphocytes sensitized to alloantigens. Nature. 1970 Dec 26;228(5278):1308–1309. doi: 10.1038/2281308a0. [DOI] [PubMed] [Google Scholar]
  4. De Landazuri M. O., Herberman R. B. Immune response to Gross virus-induced lymphoma. 3. Characteristics of the cellular immune response. J Natl Cancer Inst. 1972 Jul;49(1):147–154. [PubMed] [Google Scholar]
  5. Eckner R. J., Steeves R. A. A classification of the murine leukemia viruses. Neutralization of pseudotypes of Friend spleen focus-forming virus by type-specific murine antisera. J Exp Med. 1972 Oct 1;136(4):832–850. doi: 10.1084/jem.136.4.832. [DOI] [PMC free article] [PubMed] [Google Scholar]
  6. Fefer A., McCoy J. L., Perk K., Glynn J. P. Immunologic, virologic, and pathologic studies of regression of autochthonous Moloney sarcoma virus-induced tumors in mice. Cancer Res. 1968 Aug;28(8):1577–1585. [PubMed] [Google Scholar]
  7. Gelderblom H., Bauer H., Graf T. Cell-surface antigens induced by avian RNA tumor viruses: detection by immunoferritin technique. Virology. 1972 Feb;47(2):416–425. doi: 10.1016/0042-6822(72)90277-2. [DOI] [PubMed] [Google Scholar]
  8. Gorczynski R. M. Evidence for in vivo protection against murine-sarcoma virus-induced tumors by T lymphocytes from immune animals. J Immunol. 1974 Feb;112(2):533–539. [PubMed] [Google Scholar]
  9. Gorczynski R. M. Immunity to murine sarcoma virus-inducted tumors. I. Specific T lymphocytes active in macrophage migration inhibition and lymphocyte transformation. J Immunol. 1974 May;112(5):1815–1825. [PubMed] [Google Scholar]
  10. Gorczynski R. M. Immunity to murine sarcoma virus-inducted tumors. II. Suppression of T cell-mediated immunity by cells from progressor animals. J Immunol. 1974 May;112(5):1826–1838. [PubMed] [Google Scholar]
  11. Gorczynski R. M., Norbury C. Immunity to murine sarcoma virus induced tumours. 3. Analysis of the cell populations involved in protection from lethal tumour progression of sublethally irradiated, MSV inoculated, mice. Br J Cancer. 1974 Aug;30(2):118–128. doi: 10.1038/bjc.1974.122. [DOI] [PMC free article] [PubMed] [Google Scholar]
  12. Hellström I., Hellström K. E. Studies on cellular immunity and its serum mediated inhibition in Moloney-virus-induced mouse sarcomas. Int J Cancer. 1969 Sep 15;4(5):587–600. doi: 10.1002/ijc.2910040503. [DOI] [PubMed] [Google Scholar]
  13. Kirchner H., Chused T. M., Herberman R. B., Holden H. T., Lavrin D. H. Evidence of suppressor cell activity in spleens of mice bearing primary tumors induced by Moloney sarcoma virus. J Exp Med. 1974 Jun 1;139(6):1473–1487. doi: 10.1084/jem.139.6.1473. [DOI] [PMC free article] [PubMed] [Google Scholar]
  14. Kurth R., Bauer H. Cell-surface antigens induced by avian RNA tumor viruses: detection by a cytotoxic microassay. Virology. 1972 Feb;47(2):426–433. doi: 10.1016/0042-6822(72)90278-4. [DOI] [PubMed] [Google Scholar]
  15. LOWRY O. H., ROSEBROUGH N. J., FARR A. L., RANDALL R. J. Protein measurement with the Folin phenol reagent. J Biol Chem. 1951 Nov;193(1):265–275. [PubMed] [Google Scholar]
  16. Lamon E. W., Skurzak H. M., Klein E., Wigzell H. In vitro cytotoxicity by a nonthymus-processed lymphocyte population with specificity for a virally determined tumor cell surface antigen. J Exp Med. 1972 Nov 1;136(5):1072–1079. doi: 10.1084/jem.136.5.1072. [DOI] [PMC free article] [PubMed] [Google Scholar]
  17. Lamon E. W., Wigzel H., Klein E., Andersson B., Skurzak H. M. The lymphocyte response to primary Moloney sarcoma virus tumors in BALB-c mice. Definition of the active subpopulations at different times after infection. J Exp Med. 1973 Jun 1;137(6):1472–1493. doi: 10.1084/jem.137.6.1472. [DOI] [PMC free article] [PubMed] [Google Scholar]
  18. Law L. W., Apella E. Immunogenic properties of solubilized tumour antigen from an RNA virus-transformed neoplasm. Nature. 1973 May 11;243(5402):83–87. doi: 10.1038/243083a0. [DOI] [PubMed] [Google Scholar]
  19. Leclerc J. C., Gomard E., Plata F., Levy J. P. Cell-mediated immune reaction against tumors induced by oncornaviruses. II. Nature of the effector cells in tumor-cell cytolysis. Int J Cancer. 1973 Mar 15;11(2):426–432. doi: 10.1002/ijc.2910110220. [DOI] [PubMed] [Google Scholar]
  20. MacLennan I. C., Loewi G., Harding B. The role of immunoglobulins in lymphocyte-mediated cell damage, in vitro. I. Comparison of the effects of target cell specific antibody and normal serum factors on cellular damage by immune and non-immune lymphocytes. Immunology. 1970 Mar;18(3):397–404. [PMC free article] [PubMed] [Google Scholar]
  21. Miller R. G., Phillips R. A. Separation of cells by velocity sedimentation. J Cell Physiol. 1969 Jun;73(3):191–201. doi: 10.1002/jcp.1040730305. [DOI] [PubMed] [Google Scholar]
  22. Plata F., Levy J. P. Blocking of syngeneic effector T cells by soluble tumour antigens. Nature. 1974 May 17;249(454):271–274. doi: 10.1038/249271a0. [DOI] [PubMed] [Google Scholar]
  23. Shellam G. R., Knight R. A. Antigenic inhibition of cell-mediated cytotoxicity against tumour cells. Nature. 1974 Nov 22;252(5481):330–332. doi: 10.1038/252330a0. [DOI] [PubMed] [Google Scholar]
  24. Sjögren H. O., Hellström I., Bansal S. C., Hellström K. E. Suggestive evidence that the "blocking antibodies" of tumor-bearing individuals may be antigen--antibody complexes. Proc Natl Acad Sci U S A. 1971 Jun;68(6):1372–1375. doi: 10.1073/pnas.68.6.1372. [DOI] [PMC free article] [PubMed] [Google Scholar]
  25. Yoshiki T., Mellors R. C., Hardy W. D., Jr, Fleissner E. Common cell surface antigen associated with mammalian C-type RNA viruses. Cell membrane-bound gs antigen. J Exp Med. 1974 Apr 1;139(4):925–942. doi: 10.1084/jem.139.4.925. [DOI] [PMC free article] [PubMed] [Google Scholar]

Articles from British Journal of Cancer are provided here courtesy of Cancer Research UK

RESOURCES